CN113164394A - 一种维拉佐酮固体分散体及其制备方法 - Google Patents

一种维拉佐酮固体分散体及其制备方法 Download PDF

Info

Publication number
CN113164394A
CN113164394A CN201980080339.8A CN201980080339A CN113164394A CN 113164394 A CN113164394 A CN 113164394A CN 201980080339 A CN201980080339 A CN 201980080339A CN 113164394 A CN113164394 A CN 113164394A
Authority
CN
China
Prior art keywords
vilazodone
solid dispersion
dispersion according
carrier material
weight percentage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980080339.8A
Other languages
English (en)
Other versions
CN113164394B (zh
Inventor
方代龙
范露露
黄心
游劲松
黄芳芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN113164394A publication Critical patent/CN113164394A/zh
Application granted granted Critical
Publication of CN113164394B publication Critical patent/CN113164394B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种维拉佐酮固体分散体及其制备方法和用途，所述固体分散体包含活性成分维拉佐酮游离碱、聚合物材料和增塑剂；所述固体分散体由热熔挤出方法制得，且维拉佐酮以非结晶态存在于固体分散体中；该固体分散体能显著提高维拉佐酮的溶解度和体外溶出度，从而显著增加其口服生物利用度；所述固体分散体可用于制备维拉佐酮的相关制剂。

Description

PCT国内申请，说明书已公开。

Claims (31)

  1. PCT国内申请，权利要求书已公开。
CN201980080339.8A 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法 Active CN113164394B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115230432 2018-12-13
CN201811523043 2018-12-13
PCT/CN2019/124446 WO2020119701A1 (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法

Publications (2)

Publication Number Publication Date
CN113164394A true CN113164394A (zh) 2021-07-23
CN113164394B CN113164394B (zh) 2023-06-23

Family

ID=71075886

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980080339.8A Active CN113164394B (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法
CN201980080366.5A Active CN113164473B (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980080366.5A Active CN113164473B (zh) 2018-12-13 2019-12-11 一种维拉佐酮固体分散体及其制备方法

Country Status (3)

Country Link
US (1) US20220071993A1 (zh)
CN (2) CN113164394B (zh)
WO (2) WO2020119701A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117257804A (zh) * 2023-10-17 2023-12-22 深圳市新阳唯康科技有限公司 达拉非尼药物组合物及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023179774A1 (en) * 2022-03-25 2023-09-28 Shenzhen Pharmacin Co., Ltd. Amorphous solid dispersions and pharmaceutical compositions comprising the same
CN115581678B (zh) * 2022-11-04 2023-09-12 北京鑫开元医药科技有限公司 一种瑞派替尼片组合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
CN103211751A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 含维拉唑酮的药物组合物及其制备方法
CN104116741A (zh) * 2013-04-24 2014-10-29 江苏先声药物研究有限公司 盐酸维拉佐酮组合物及其制备方法
CN104523620A (zh) * 2014-12-14 2015-04-22 天津市康瑞药业有限公司 维拉佐酮滴丸及其制备方法
US20170217939A1 (en) * 2012-05-11 2017-08-03 Dr. Reddy's Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
CN108078934A (zh) * 2017-12-26 2018-05-29 南京工业大学 一种盐酸齐拉西酮固体分散片及其热熔挤出方法
WO2018127088A1 (en) * 2017-01-06 2018-07-12 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854649A1 (en) * 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
IN2013MU03458A (zh) * 2013-10-31 2015-07-17 Lupin Ltd
CN106540266A (zh) * 2015-09-18 2017-03-29 天津市汉康医药生物技术有限公司 一种维拉佐酮药物组合物及其制备方法
CN106580895A (zh) * 2016-12-07 2017-04-26 万全万特制药（厦门）有限公司 含盐酸维拉佐酮固体分散体的口腔崩解片及其制备方法
CN106580914A (zh) * 2017-02-27 2017-04-26 佛山市弘泰药物研发有限公司 一种盐酸维拉佐酮软胶囊及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
US20170217939A1 (en) * 2012-05-11 2017-08-03 Dr. Reddy's Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
CN103211751A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 含维拉唑酮的药物组合物及其制备方法
CN104116741A (zh) * 2013-04-24 2014-10-29 江苏先声药物研究有限公司 盐酸维拉佐酮组合物及其制备方法
CN104523620A (zh) * 2014-12-14 2015-04-22 天津市康瑞药业有限公司 维拉佐酮滴丸及其制备方法
WO2018127088A1 (en) * 2017-01-06 2018-07-12 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
CN108078934A (zh) * 2017-12-26 2018-05-29 南京工业大学 一种盐酸齐拉西酮固体分散片及其热熔挤出方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李妍妍 等: "聚合物/表面活性剂二元载体的固体分散体提高普罗布考的溶出度", 《沈阳药科大学学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117257804A (zh) * 2023-10-17 2023-12-22 深圳市新阳唯康科技有限公司 达拉非尼药物组合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2020119701A1 (zh) 2020-06-18
CN113164473A (zh) 2021-07-23
CN113164394B (zh) 2023-06-23
US20220071993A1 (en) 2022-03-10
CN113164473B (zh) 2024-08-23
WO2020119698A1 (zh) 2020-06-18

Similar Documents

Publication Publication Date Title
AU2021277731B2 (en) Improved formulations of deferasirox and methods of making the same
RU2351316C2 (ru) Лекарственные формы с замедленным высвобождением зипразидона
JP2019194262A (ja) エンザルタミドの製剤
EP2180882B1 (en) Solid matrix pharmaceutical preparation
CN113164394A (zh) 一种维拉佐酮固体分散体及其制备方法
US8663698B2 (en) Solid dispersion preparation
US20070248682A1 (en) Solid preparation comprising enteric solid dispersion
JP2011530532A (ja) 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物
US10034883B2 (en) Mesoporous dosage forms for poorly soluble drugs
EP1691786A1 (en) Multiparticulate compositions with improved stability
WO2019128991A1 (en) Lurasidone solid dispersion and preparation method thereof
US20220211725A1 (en) Pharmaceutical Composition Comprising Venetoclax
CN114948960A (zh) 一种维拉佐酮的组合物及其制备方法
CN114533735A (zh) 盐酸鲁拉西酮药物组合物及其制备方法
WO2022049075A1 (en) Amorphous solid dispersion of darolutamide
WO2015163689A1 (ko) 활성 성분 (i) 함유 조성물 및 이의 제조 방법
CA3160834A1 (en) Amorphous pharmaceutical compositions of abiraterone acetate
RU2792098C1 (ru) Способ получения фармацевтической композиции с такролимусом (варианты) и фармацевтическая композиция, полученная указанными способами

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan City, Guangdong Province

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.